No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas

Journal of Neuro-Oncology

Volumn 109, Issue 1, 2012, Pages 15-22

  Ahmadi, Rezvan ^a   Stockhammer, Florian ^b   Becker, Natalia ^c   Hohlen, Katarina ^d   Misch, Martin ^d   Christians, Arne ^c   Dictus, Christine ^a   Herold Mende, Christel ^a   Capper, David ^a,c   Unterberg, Andreas ^a   Von Deimling, Andreas ^a,c   Wick, Wolfgang ^a   Hartmann, Christian ^e  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Astrocytoma WHO grade II; IDH1; IDH2; Overall survival; Progression free survival

Indexed keywords

ISOCITRATE DEHYDROGENASE 1;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IDH1 GENE; IDH2 GENE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; WORLD HEALTH ORGANIZATION;

EID: 84864281784     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0863-y     Document Type: Article

References (24)

1. Louis DN, International Agency for Research on Cancer (2007) WHO classification of tumours of the central nervous system. World Health Organization classification of tumours, 4th edn. International Agency for Research on Cancer, Lyon
2. F Pignatti M van den Bent D Curran C Debruyne R Sylvester P Therasse D Afra P Cornu M Bolla C Vecht AB Karim 2002 Prognostic factors for survival in adult patients with cerebral low-grade glioma J Clin Oncol 20 8 2076 2084 11956268 10.1200/JCO.2002.08.121 (Pubitemid 34408798)
3. A Peraud FW Kreth OD Wiestler P Kleihues HJ Reulen 2002 Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas Clin Cancer Res 8 5 1117 1124 12006527 1:CAS:528:DC%2BD38XksVSqu7g%3D (Pubitemid 34517648)
4. M Ständer A Peraud B Leroch FW Kreth 2004 Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis Cancer 101 5 1028 1035 15329912 10.1002/cncr.20432 (Pubitemid 39100437)
5. DW Parsons S Jones X Zhang JC Lin RJ Leary P Angenendt P Mankoo H Carter IM Siu GL Gallia A Olivi R McLendon BA Rasheed S Keir T Nikolskaya Y Nikolsky DA Busam H Tekleab LA Diaz Jr J Hartigan DR Smith RL Strausberg SK Marie SM Shinjo H Yan GJ Riggins DD Bigner R Karchin N Papadopoulos G Parmigiani B Vogelstein VE Velculescu KW Kinzler 2008 An integrated genomic analysis of human glioblastoma multiforme Science 321 5897 1807 1812 18772396 10.1126/science. 1164382 1:CAS:528:DC%2BD1cXhtFCrtLrE
6. J Balss J Meyer W Mueller A Korshunov C Hartmann A von Deimling 2008 Analysis of the IDH1 codon 132 mutation in brain tumors Acta Neuropathol 116 6 597 602 18985363 10.1007/s00401-008-0455-2 1:CAS:528:DC%2BD1cXhtlyhsbfN
7. T Watanabe S Nobusawa P Kleihues H Ohgaki 2009 IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas Am J Pathol 174 4 1149 1153 19246647 10.2353/ajpath.2009.080958 1:CAS:528:DC%2BD1MXksVOksLY%3D
8. H Yan DW Parsons G Jin R McLendon BA Rasheed W Yuan I Kos I Batinic-Haberle S Jones GJ Riggins H Friedman A Friedman D Reardon J Herndon KW Kinzler VE Velculescu B Vogelstein DD Bigner 2009 IDH1 and IDH2 mutations in gliomas N Engl J Med 360 8 765 773 19228619 10.1056/NEJMoa0808710 1:CAS:528:DC%2BD1MXitFWru7o%3D
9. C Hartmann J Meyer J Balss D Capper W Mueller A Christians J Felsberg M Wolter C Mawrin W Wick M Weller C Herold-Mende A Unterberg JW Jeuken P Wesseling G Reifenberger A von Deimling 2009 Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas Acta Neuropathol 118 4 469 474 19554337 10.1007/s00401-009-0561-9
10. A Korshunov J Meyer D Capper A Christians M Remke H Witt S Pfister A von Deimling C Hartmann 2009 Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma Acta Neuropathol 118 3 401 405 19543740 10.1007/s00401-009-0550-z 1:CAS:528:DC%2BD1MXptVGjt7c%3D
11. C Hartmann B Hentschel M Tatagiba J Schramm O Schnell C Seidel R Stein G Reifenberger T Pietsch A von Deimling M Loeffler M Weller 2011 Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 17 13 4588 4599 21558404 10.1158/1078-0432.CCR-10-3194 1:CAS:528:DC%2BC3MXos1Smur4%3D
12. YH Kim S Nobusawa M Mittelbronn W Paulus B Brokinkel K Keyvani U Sure K Wrede Y Nakazato Y Tanaka A Vital L Mariani R Stawski T Watanabe U De Girolami P Kleihues H Ohgaki 2010 Molecular classification of low-grade diffuse gliomas Am J Pathol 177 6 2708 2714 21075857 10.2353/ajpath.2010.100680
13. M Labussiere A Idbaih XW Wang Y Marie B Boisselier C Falet S Paris J Laffaire C Carpentier E Criniere F Ducray S El Hallani K Mokhtari K Hoang-Xuan JY Delattre M Sanson 2010 All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 Neurology 74 23 1886 1890 20427748 10.1212/WNL.0b013e3181e1cf3a 1:CAS:528:DC%2BC3cXntF2gtbw%3D
14. P Metellus B Coulibaly C Colin AM de Paula A Vasiljevic D Taieb A Barlier B Boisselier K Mokhtari XW Wang A Loundou F Chapon S Pineau L Ouafik O Chinot D Figarella-Branger 2010 Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis Acta Neuropathol 120 6 719 729 21080178 10.1007/s00401-010-0777-8
15. Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A, Kreth FW (2011) IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer. doi: 10.1002/cncr.26298
16. M Sanson Y Marie S Paris A Idbaih J Laffaire F Ducray S El Hallani B Boisselier K Mokhtari K Hoang-Xuan JY Delattre 2009 Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas J Clin Oncol 27 25 4150 4154 19636000 10.1200/JCO.2009.21.9832 1:CAS:528:DC%2BD1MXhtF2jtLrP
17. M Weller J Felsberg C Hartmann H Berger JP Steinbach J Schramm M Westphal G Schackert M Simon JC Tonn O Heese D Krex G Nikkhah T Pietsch O Wiestler G Reifenberger A von Deimling M Loeffler 2009 Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the german glioma network J Clin Oncol 27 34 5743 5750 19805672 10.1200/JCO.2009.23.0805 1:CAS:528:DC%2BC3cXhtVWisbg%3D
18. W Wick C Hartmann C Engel M Stoffels J Felsberg F Stockhammer MC Sabel S Koeppen R Ketter R Meyermann M Rapp C Meisner RD Kortmann T Pietsch OD Wiestler U Ernemann M Bamberg G Reifenberger A von Deimling M Weller 2009 NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide J Clin Oncol 27 35 5874 5880 19901110 10.1200/JCO.2009.23.6497 1:CAS:528:DC%2BC3cXhtVWis7g%3D
19. MJ van den Bent HJ Dubbink Y Marie AA Brandes MJ Taphoorn P Wesseling M Frenay CC Tijssen D Lacombe A Idbaih R van Marion JM Kros WN Dinjens T Gorlia M Sanson 2010 IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group Clin Cancer Res 16 5 1597 1604 20160062 10.1158/1078-0432.CCR-09-2902
20. C Hartmann B Hentschel W Wick D Capper J Felsberg M Simon M Westphal G Schackert R Meyermann T Pietsch G Reifenberger M Weller M Loeffler A von Deimling 2010 Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas Acta Neuropathol 120 6 707 718 21088844 10.1007/s00401-010-0781-z
21. D Capper D Reuss J Schittenhelm C Hartmann J Bremer F Sahm PN Harter A Jeibmann A von Deimling 2011 Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology Acta Neuropathol 121 2 241 252 21069360 10.1007/s00401-010-0770-2
22. C Hartmann A von Deimling 2009 Molecular pathology of oligodendroglial tumors Recent Results Cancer Res 171 25 49 19322536 10.1007/978-3-540-31206-2-2
23. HJ Dubbink W Taal R van Marion JM Kros I van Heuvel JE Bromberg BA Zonnenberg CB Zonnenberg TJ Postma JM Gijtenbeek W Boogerd FH Groenendijk PA Smitt WN Dinjens MJ van den Bent 2009 IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide Neurology 73 21 1792 1795 19933982 10.1212/WNL.0b013e3181c34ace 1:CAS:528:DC%2BD1MXhsVaks77K
24. K Ichimura DM Pearson S Kocialkowski LM Backlund R Chan DT Jones VP Collins 2009 IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas Neuro Oncol 11 4 341 347 19435942 10.1215/15228517-2009-025 1:CAS:528:DC%2BD1MXhtV2qur%2FF